Tropical Lymphedemas — Control and Prevention by Molyneux, David
Perspective 
The NEW ENGLAND JOURNAL of MEDICINE
march 29, 2012
n engl j med 366;13 nejm.org march 29, 2012 1169
Wuchereria bancrofti (and, in Asia, 
Brugia malayi and B. timori), which 
is transmitted by mosquitoes. The 
second principal cause is podo-
coniosis.
Lymphatic filariasis is endem-
ic in some 72 countries through-
out the tropics (see map), and an 
estimated 1.39 billion people live 
in areas of risk.1 An estimated 
40 million people have stigmatiz-
ing and disabling clinical manifes-
tations of the infection: 15 mil-
lion have elephantiasis, and some 
25 million men have genital swell-
ing, usually scrotal hydrocele.1 The 
current strategy for stopping 
transmission is the annual mass 
administration of donated drugs 
— albendazole and ivermectin in 
areas of Africa where onchocer-
ciasis is coendemic, and diethyl-
carbamazine and albendazole 
elsewhere.
The Global Program to Elimi-
nate Lymphatic Filariasis (GPELF), 
begun in 2000, is aimed at elimi-
nating transmission of the infec-
tion and reducing associated ill-
nesses. Through annual mass 
distribution of drugs, substantial 
progress has been made in 
12 years toward the elimination 
target set by the GPELF, with 
about 466 million people treated 
in 2010. The economic benefits 
accrued through the program 
from 2000 through 2008, in-
cluding the ancillary benefits of 
 deworming and the impact on 
scabies, have been calculated at 
$24 billion. Costs per year for 
control of lymphatic filariasis 
range from $0.06 to $1.00 per 
person, depending on the set-
ting; as with other neglected trop-
ical diseases, costs of preventive 
chemotherapy are general ly less 
than $0.50 per person per year. 
Therefore, prevention of lymphatic 
filariasis ranks among the most 
cost-effective global health inter-
ventions, along with deworming 
and onchocerciasis prevention, 
as measured in cost per disabil-
ity-adjusted life-year averted.2
Lymphatic filariasis is one of 
17 neglected tropical diseases that 
afflict the world’s poorest peo-
ple, but another even more ne-
glected condition causing ele-
phantiasis has been highlighted 
in recent years — podoconiosis, 
which affects some 4 million peo-
ple in Africa, Latin America, and 
a few areas of Asia3 (see map). For 
many years, podoconiosis was 
relegated to the small print of 
even specialist tropical medicine 
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textbooks, but it has emerged as 
an important cause of illness in 
communities where people are ex-
posed to irritant, red-clay, volcanic 
soil. Microsilica particles from the 
soil enter the body through the 
skin of the feet and cause chronic 
obstruction of the lymphatics.
The article by Tekola Ayele et al. 
in this issue of the Journal (pages 
1200–1208) highlights the role of 
genetics in the predisposition to 
this condition. The authors found 
a significant association of podo-
coniosis with particular genetic 
variants in the HLA class II re-
gion, and they found that certain 
single-nucleotide polymorphisms 
increase the risk of clinical dis-
ease by a factor of two to three. 
Affected people have symptoms 
similar to those associated with 
filarial lymphedema: adenolym-
phangitis, plantar edema, moss-
like papillomas (“mossy foot”), 
and multiple skin nodules, with 
progression to a hard, fibrotic 
leg (see photo). Podoconiosis must 
be distinguished from filarial 
lymphedema — it is found at alti-
tudes higher than those at which 
mosquitoes can transmit filarial 
infection (a maximum of about 
1500 m). The study by Tekola Ayele 
et al. highlights the importance of 
examining the human genetics of 
disease in resource-poor areas to 
enable the targeting of interven-
tions, which in this case are as 
simple as providing shoes to peo-
ple with a family history of podo-
coniosis. Previous work in Ethi-
opia revealed the social and 
economic effects of the disease — 
affected people have a markedly 
reduced earning capacity.
More than 705 million people 
received integrated preventive che-
motherapy for at least one ne-
glected tropical disease in 2009, 
and 702 million to 715 million did 
so in 2010.4 More than 800 mil-
lion people are treated annually 
for some form of helminth dis-
ease or trachoma, according to 
the World Health Organization, 
and more than half of them are 
treated for lymphatic filariasis. 
Expansion of the lymphatic fila-
riasis program in Central Africa, 
and in the Democratic Republic 
of the Congo and Cameroon in 
particular, is constrained by the 
risk of severe adverse reactions, 
manifested as encephalopathy, to 
treatment with ivermectin among 
persons with high microfilarial 
loads of the tropical eye worm 
Loa loa. This problem was initially 
identified in onchocerciasis-con-
trol programs during the mid-
1990s and has prevented large-
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Global Distribution of Lymphatic Filariasis (LF) and Podoconiosis and Status of Mass Administration of Drugs (MDA), 2009.
Data are from the World Health Organization. Dots represent various island nations.
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scale treatment for lymphatic 
filariasis because of the potential 
coendemicity of W. bancrofti and 
L. loa in Central Africa.
Whereas annual mass drug ad-
ministration relies on the ability 
of drugs to reduce microfilaria 
loads to levels at which transmis-
sion is reduced, a high-priority 
need is for a drug that kills or 
permanently sterilizes the adult 
worms — a macrofilaricide. It is 
known that some filarial nema-
todes contain the endosymbiotic 
bacteria wolbachia, which have 
become targets for chemother-
apy, since they have also been 
implicated as contributors to the 
pathogenesis of inflammatory 
disease. Doxycycline is effective 
when given daily over a 6-week 
period, since it kills or sterilizes 
adult filaria of both Onchocerca 
volvulus and W. bancrofti. Ongoing 
research is seeking to reduce the 
duration of antibiotic treatment 
and to find a less toxic product 
that might be given over a short-
er period and be amenable to ad-
ministration by the communities 
themselves, as treatments for on-
chocerciasis and lymphatic filari-
asis are. Although the current 
drugs (albendazole, ivermectin, 
and diethylcarbamazine) are de-
signed to be given for the dura-
tion of the adult worms’ life (an 
estimated 5 to 8 years) and at a 
coverage level of 75% of the pop-
ulation in all geographic areas 
where they are endemic, they also 
have an effect on clinical disease: 
they reduce the frequency of fi-
larial fevers, the size of scrotal 
hydrocele, and in children, sub-
clinical lymphatic damage.
One of the challenges for the 
GPELF has been that disease-
control programs that address 
the needs of patients with exist-
ing clinical lymphedema or hydro-
cele have lagged behind mass 
drug distribution. It is critical that 
this gap be addressed. The drivers 
of success will be maintenance of 
high coverage, provision of re-
sources for monitoring and eval-
uation, and efforts to understand 
the complexity of the interactions 
among coendemic conditions such 
as lymphatic filariasis, onchocer-
ciasis, and soil-transmitted hel-
minths; control or elimination 
interventions for all these condi-
tions benefit from donated drugs. 
The success of lymphatic filaria-
sis programs in Africa will also 
be influenced by the extent of 
coverage with bed nets impreg-
nated with long-lasting insecti-
cide, which, if distributed widely, 
could probably reduce the required 
number of annual mass drug ad-
ministrations.
Over the past decade, there 
has been remarkable progress in 
addressing lymphatic filariasis as 
a global problem. Several billion 
doses of drugs have been donated 
and delivered, and they have had 
the additional benefit of effective 
deworming. Still, programs pro-
viding surgery for scrotal hydro-
cele need to be scaled up, and 
access to lymphedema-manage-
ment programs must be increased. 
The lymphatic filariasis commu-
nity is aware of the need for 
 improved therapy, especially a 
macrofilaricide, as well as the 
challenges of scaling up programs 
in countries that are recovering 
from conflict and civil unrest 
and of the need to expand dis-
ease control, address the L. loa 
issue, enhance coverage, and 
monitor and evaluate impact. 
Certification of the absence of 
transmission awaits detailed 
transmission-assessment surveys. 
Research into improving the cost-
effectiveness of elimination pro-
grams will continue, and their 
lessons need to be not only 
learned but also applied.
The two tropical lymphedemas, 
filariasis and podoconiosis, are 
now on the radar screen for global 
health. The two conditions share 
clinical features and challenges 
that are similar to highly dis-
abling conditions affecting the 
most disadvantaged communities, 
and they inflict similar social 
problems. It may be possible, 
however, to eliminate both dis-
eases. The idea that impover-
ished people might wear shoes 
may seem self-evident, but being 
able to target the people at great-
est risk represents considerable 
progress.
Disclosure forms provided by the author 
are available with the full text of this arti-
cle at NEJM.org.
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